Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
INHIBITORS OF PI3 KINASES
Document Type and Number:
WIPO Patent Application WO/2017/090002
Kind Code:
A4
Abstract:
The present invention is directed to the compounds of Formula (I) or isomers, stereoisomers, tautomers, pharmaceutically acceptable salts, isotopes, solvates, metabolites, polymorphs or prodrugs thereof, wherein R1, R2, R3, R4, /A, B, L1, L2, Z, n and X are herein defined as inhibitors of PI3K. These compounds are used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of PI3K's such as Inflammation, Cancer, Restenosis, Atherosclerosis, Psoriasis, Thrombosis, immmuno-oncology, renal carcinoma, hepatitis C, haematological malignancies, and multiple myeloma.

Inventors:
JOSHI HEMANT (IN)
DURAISWAMY ATHISAYAMANI JEYARAJ (IN)
BETHI REDDY SRIDHAR (IN)
ROY CHOWDHURY ARNAB (IN)
Application Number:
PCT/IB2016/057134
Publication Date:
April 19, 2018
Filing Date:
November 25, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
GVK BIOSCIENCES PRIVATE LTD (IN)
International Classes:
C07D265/36; C07D311/32; C07D311/58
Attorney, Agent or Firm:
TALWAR, Jitin (IN)
Download PDF:
Claims:
AMENDED CLAIMS

received by the International Bureau on 1st March 2018 (01.03.18)

1 . A compound of Formula (I)

or isomers, stereoisomers, tautomers, or pharmaceutically acceptable salts, isotopes, solvates, metabolites, polymorphs or prodrugs thereof, wherein:

A is selected from CO, Chb;

B is selected from O, S, C, N;

Z is selected from CRi , N;

X is selected from bond, O, NR3, CR3R3, and SO2NR3; Li , l_2 is independently selected from CO, NR5, and CR5R5; n is an integer between 0 and 2, inclusive;

Ri is selected from H, alkyl, substituted alkyl, alkenyl, alkynyl, haloalkyl, halogen, amine, aminocarbonyl, nitrile, haloalkoxy, hydroxyalkyi, alkoxycarbonyl, optionally substituted aminocarbonyl, cyano, optionally substituted phenyl, cycloalkyl, carboxylic acid, CH2COOH, NHCONR5, Ch CONh Coptionally substituted with alkyl, aryl, halogenated aryl, heteroaryh.-OCh CONI- , - NHCORs, -NHCH2CF3, -NHChbPh, Tetrazole, any heterocycle, any fused heterocycle, OR5, CORs, R3SO2NH, S02NHR5,B(OH)2;

R2 is selected from aminocarbonyl, nitrile, hydroxyalkyi, alkoxycarbonyl, optionally substituted aminocarbonyl, NHCONR5, any heterocycle, any fused heterocycle; R3 is selected from H, alkyl, aryl, alkyl aryl, optionally substituted aryl, alkyl, halogen, haloalkyl, branched alkyl, acetyl, benzoyl, cycloalkyi;

R4 is selected from aryl, optionally substituted aryl, alkylaryl, arylalkyi, cycloalkyi, heteroaryl, optionally substituted heteroaryl , optionally substituted alkylaryl, 3-6 membered heterocyclic ring with one or more heteroatom selected from O, N and S and optionally substituted with one or more substituent's independently selected from H, alkyl, alkenyl, alkynyl, haloalkyl, halogen, hydroxy, alkoxy, haloalkoxy, carboxylic acid, carboxamide;

R5 is selected from H, alkyl, halogen, haloalkyl, hydroxy, hydroxyalkyl, alkoxycarbonyl, aminocarbonyl, amino, alkylaryl, substituted alkyl, substituted alkyl aryl, aryl, substituted aryl, alkyl carboxylic acid, alkylamide, alkylamine, alkyl nitrile, cycloalkyi, optionally substituted cycloalkyi; and wherein Ri forms a six membered ring with Li

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

3. The pharmaceutical composition as claimed in claim 2, wherein said composition is used for prevention and/or therapeutic treatment of diseases or disorders associated with abnormal activities of PI3 kinases.

4. The pharmaceutical composition as claimed in claim 3, wherein said diseases or disorders are associated with abnormal activities of PI3 kinases, especially possessing inhibitory activity against ΡΙ3Κβ.

5. The pharmaceutical composition as claimed in claim 3, wherein said diseases or disorders are selected from the group consisting of Inflammation, Cancer, Restenosis, Atherosclerosis, Psoriasis, Thrombosis, immmuno-oncology, renal carcinoma, hepatitis C, haematological malignancies, and multiple myeloma.

6. A method for treating a disease or disorder associated with abnormal activities of PI3K's activity wherein said disease or disorder is selected from the group consisting of Inflammation, Cancer, Restenosis, Atherosclerosis, Psoriasis, Thrombosis, immuno-oncology, renal carcinoma, hepatitis C, hematological malignancies, multiple myeloma or a disease or a disorder associated with abnormal activities of PI3K signaling in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7. The method as claimed in Claim 6, wherein said cancer is selected from the group consisting of lung Adenocarcinomas, Breast Cancer, Thyroid Carcinoma, Pancreatic Cancer, Ovarian Carcinoma, Malignant Mesothelioma, Prostate, Neuroblastic Tumors, Colorectal Carcinoma, Spitzoid Melanoma, Salivary Adenoid Cystic Carcinoma Glioblastoma Multiforme, Oral Squamous Cell Carcinoma, Acute Myeloid Leukemia.

8. A compound which is:

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4- one

> 5-hydroxy-2-methyl-7-morpholino-2-(p-tolyloxymethyl)chroman-4-one

> 2-(benzyloxymethyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> 5-hydroxy-2-methyl-7-morpholino-2-(m-tolyloxymethyl)chroman-4-one

> 5-hydroxy-2-methyl-2-(4-methylbenzyl)-7-morpholinochroman-4-one

> 2-((4-fluorophenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-7-morpholino-2-((2-(trifluoromethyl)phenoxy)methyl)chroman-4- one

> 5-hydroxy-2-methyl-7-morpholino-2-((3-(trifluoromethyl)phenoxy)methyl)chroman-4- one

> 2-(3-fluorobenzyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-benzyl-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-7-morpholino-2-phenethylchroman-4-one

> 2-((4-chlorophenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-((4-(dimethylamino)phenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-chroman-4- one

> N-((5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)methyl)benzamide

> N-benzyl-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-carboxamide

> 5-hydroxy-2,2-dimethyl-7-morpholinochroman-4-one

> N-((5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)methyl)-N-phenylacetamide

> 2-((3-(dimethylamino)phenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4- one

> 5-hydroxy-2-(4-methoxybenzyl)-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-7-morpholino-2-((phenylamino)methyl)chroman-4-one > 2-((4-chlorophenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-((4-(dimethylamino)phenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-chroman-4- one

> 1 -(5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)-N^henylmethanesulfonamide

> 2-((4-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-2-((2-methyl-3-(trifluoromethyl)phenoxy)methyl)-7-morpholinoch

one

> 2-((3-chloro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 5-hydroxy-2-methyl-2-((methyl(phenyl)amino)methyl)-7-morpholinochroman-4-one

> N-benzyl-N-((5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)methyl)acetamide

> 5-hydroxy-2-methyl-7-morpholino-2-(phenoxymethyl)chroman-4-one

> 2-((2-fluoro-3-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-((5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)methoxy)benzoic acid

> 2-((5-hydroxy-2-methyl-7-morpholino-4-oxochroman-2-yl)methoxy)-N,N-dimethylbenzamide

> 2-((3,5-difluorophenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-((2,5-difluorophenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5- carboxylic acid

> 2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-carboxamide

> 2-methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-5-yl trifluoromethanesulfonate

> 2-((3-fluoro-2-methylphenoxy)methyl)-N,2-dimethyl-7-morpholino-4-oxochroman-5-carboxamide

> 2-((3-fluoro-2-methylphenoxy)methyl)-N,N,2-trimethyl-7-morpholino-4-oxochroman-5- carboxamide

> 2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-5-carboxamide

> 2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-5-carboxylic acid

> 2-methyl-7-morpholino-4-oxo-2-((2-(trifluoromethyl)phenoxy)methyl)chroman-5-carboxamid

> 2-((3-fluoro-2-methylphenoxy)methyl)-N-hydroxy-2-methyl-7-morpholino-4-oxochromane-5- carboxamide

> 8-((3-fluoro-2-methylphenoxy)methyl)-8-methyl-5-morpholino-8,9-dihydropyrano[4,3,2- de]phthalazin-3(2H)-one

> 8-((3-fluoro-2-methylphenoxy)methyl)-8-methyl-5-morpholino-8,9-dihydro-3H-chromeno[4,5

[1 ,2] oxazin-3-one > 2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-m

acid

> Ethyl2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman -5-yloxy) acetate

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5- yloxy)acetamide

> 2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-carbonitrile

> 2-((3-Fluoro-2-methylphenoxy) methyl)-2-methyl-7-morpholino-5-(1 H-tetrazol-5-yl) chroman-4- one

> 5-(Aminomethyl)-2-((3-fluoro-2-methylphenoxy) methyl)-2-methyl-7-morpholinochroman-4-one

> 2-Methyl-7-morpholino-2-(o-tolyloxymethyl) chroman-4-one

> 5-(Benzylamino)-2-((3-fluoro-2-methylphenoxy) methyl)-2-methyl-7-morpholinochroman-4-one

> 5-Amino-2-((3-fluoro-2-methylphenoxy) methyl)-2-methyl-7-morpholinochroman-4-one

> 2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-5-(2,2,2- trifluoroethylamino)chroman-4-one

> N-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-yl)acetamide

> N-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5- yl)methanesulfonamide

> 1 -(2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-yl)urea

> 5-amino-2-methyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> (2-Methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-5-yl)boronic acid

> Ethyl 2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5- yhacetate

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-yl)acetic acid

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-5-yl)acetamide

> 6-chloro-5-hydroxy-2-methyl-7-morpholino-2-(o-tolyloxymethyl) chroman-4-one

> 8-chloro-5-hydroxy-2-methyl-7-morpholino-2-((o-tolyloxy)methyl)chroman-4-one

> 6-fluoro-5-hydroxy-2-methyl-7-morpholino-2-((o-tolyloxy)methyl)chroman-4-one

> 6-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one

> 6-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholinochroman-4-one > Ethyl2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4- oxochroman- 3-yl) acetate

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholinochroman-4-one

> 2-(2-((3-Fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-3- yl)acetic acid

> 2-(2-((3-Fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-3- yl)acetamide

> 5- hydroxy-2,3-dimethyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> 5- hydroxy-2,3,3-trimethyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetamide

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetic acid

> 3- ethyl-5-hydroxy-2-methyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> 2- (5-methoxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetic acid

> 3- cyclopropyl-5-hydroxy-2-methyl-7-morpholino-2-(o-tolyloxymethyl)chroman-4-one

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetamide

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetamide

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetamide

> 2- (5-hydroxy-2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetonitrile

> 2- (2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-3- yl)acetonitrile

> 3-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-3- yl)propanamide

> 3-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxochroman-3- yl)propanoic acid

> 2-(2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-3-yl)acetic acid

> 2-(2-((3-Fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-3-yl)acetamide

> 2-(2-methyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-3-yl)acetic acid

> 3-(Carboxymethyl)-2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman- 5-carboxylic acid > 3-(2-Amino-2-oxoethyl)-2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-^^ oxochroman-5-carboxamide

> 2,3-dimethyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-5-carboxamide

> 2,3-dimethyl-7-morpholino-4-oxo-2-(o-tolyloxymethyl)chroman-5-carboxylic acid

> 2-((3-fluoro-2-methylphenoxy)methyl)-2,3-dimethyl-7-morpholino-4-oxochroman-5-carboxam

> 2-((3-fluoro-2-methylphenoxy)methyl)-2,3-dimethyl-7-morpholino-4-oxochromane-5-carbon

> 5-amino-2-((3-fluoro-2-methylphenoxy)methyl)-2,3-dimethyl-7-morpholinochroman-4-^

> 2-(5-cyano-2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino-4-oxochroman-3- yl)acetamide

> 1 -(2-((3-fluoro-2-methylphenoxy)methyl)-2,3-dimethyl-7-morpholino-4-oxochroman-5-yl)ur^

> 3-(cyanomethyl)-2-((3-fluoro-2-methylphenoxy)methyl)-2,3-dimethyl-7-morpholino-4- oxochromane-5-carbonitrile

> 2-(8-((3-fluoro-2-methylphenoxy)methyl)-8-methyl-5-morpholino-3-oxo-2,3,8,9- tetrahydropyrano[4,3,2-de]phthalazin-9-yl)acetic acid

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-3-(hydroxymethyl)-2-methyl-7- morpholinochroman-4-one

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-2H-benzo[e][1 ,3]oxazin- 4(3H)-one

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-methoxy-2,3-dimethyl-7-morpholino-2H- benzo[e][1 ,3]oxazin-4(3H)-one

> 2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-2H- benzo[e][1 ,3]oxazin-4(3H)-one

> ethyl 2-(5-(2-ethoxy-2-oxoethoxy)-2-((3-fluoro-2-methylphenoxy)methyl)-2-methyl-7-morpholino- 4-oxo-2H-benzo[e][1 ,3]oxazin-3(4H)-yl)acetate

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4-oxo-2H- benzo[e][1 ,3]oxazin-3(4H)-yl)acetic acid

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4-oxochroman-3- yl)acetic acid

> ethyl 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4- oxochroman-3-yl)acetate > 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3^

yl)acetamide

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4-oxochroman-3 yl)acetonitrile

> 3-((1 H-tetrazol-5-yl)methyl)-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7- morpholinochroman-4-one

> 2-(6-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4- oxochroman-3-yl)acetic acid

> 2-(8-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4- oxochroman-3-yl)acetic acid

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4-oxochroman-3- yl)-N,N-dimethylacetamide

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4-oxochroman-3- yl)-N-methylacetamide

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholino-4-oxochroman-3- yl)-N-(2-hydroxyethyl)-N-methylacetamide

> 5-hydroxy-2-methyl-7-morpholino-2-((o-tolyloxy)methyl)chroman-4-one-3,3-d2

> tert-Butyl2-(5-hydroxy-2-methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-3-yl-3-d) acetate

> 2-(5-hydroxy-2-methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-3-yl-3-d)acetic acid

> 6-fluoro-5-hydroxy-2-methyl-7-morpholino-2-((o-tolyloxy)methyl)chroman-4-one-3,3-d2

> tert-butyl 2-(6-fluoro-5-hydroxy-2-methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-3-yl- 3-d) acetate

> 2-(6-fluoro-5-hydroxy-2-methyl-7-morpholino-4-oxo-2-((o-tolyloxy)methyl)chroman-3-yl-3- d)acetic acid

> 3-((2H-tetrazol-5-yl)methyl)-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7- morpholinochroman-4-one-3-d

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-m

3-d)acetic acid > 2-(6-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4- oxochroman-3-yl-3-d)acetic acid

> 2-(3,6-difluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4- oxochroman-3-yl)acetic acid

> 2-(3-fluoro-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2-methyl-7-morpholino-4- oxochroman-3-yl)acetic acid

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-(3-methylmorpholino)-4- oxochroman-3-yl)acetic acid

> 2-(2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-4-oxo-7-(3- oxomorpholino)chroman-3-yl)acetic acid

> 3-benzyl-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7-morpholinochroman- 4-one

> 3-(2-(dimethylamino)ethyl)-2-((3-fluoro-2-methylphenoxy)methyl)-5-hydroxy-2,3-dimethyl-7- morpholinochroman-4-one

> 2-(5-hydroxy-2,3-dimethyl-7-morpholino-4-oxo-2-(phenoxymethyl)-3,4-dihydro-2H-pyrano[3,2- c]pyridin-3-yl)acetic acid